INTEGRATED BIOTHERAPEUTICS, LLC
- ROCKVILLE, MD 20850-3855
- ibtbioservices.com (company website, opens in a new tab)
- Partnership or Limited Liability Partnership
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
- Small Disadvantaged Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
INTEGRATED BIOTHERAPEUTICS, LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About INTEGRATED BIOTHERAPEUTICS, LLC
- Headquarters
- ROCKVILLE, MD 20850-3855
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIXNTHMSN2JJP5
- CAGE463Q7
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 26 awards
- Total awarded
- $16,968,326
- By phase
- SBIR Phase I: 17
- STTR Phase I: 5
- SBIR Phase II: 2
- STTR Phase II: 2
- By agency
- Department of Health and Human Services: 24
- Department of Defense: 2
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2021: 1
- 2020: 1
- 2019: 5
- 2018: 1
- 2017: 3
- 2016: 2
- 2015: 1
- 2014: 1
- 2013: 1
- 2012: 3
- 2011: 1
- 2010: 1
- 2008: 1
- 2007: 1
- 1993: 2
- 1992: 1
Awards (most recent first)
Development of a Universal Immunotherapeutic for Influenza Viruses
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $1,535,553
Apr 8, 2021 – Mar 31, 2023
Solicitation PA18-574 (2018) · Topic NIAID
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $591,784
Jul 6, 2020 – Jun 30, 2022
Solicitation PA19-270 (2019) · Topic NIAID · Research partner: WASHINGTON UNIVERSITY
Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $600,000
Jul 12, 2019 – Jun 30, 2021
Solicitation PA18-575 (2018) · Topic NIAID · Research partner: UNIVERSITY OF MARYLAND BALTIMORE
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,963,566
Jul 5, 2019 – Jun 30, 2022
Solicitation PA18-575 (2018) · Topic NIAID · Research partner: UNIVERSITY OF MARYLAND UNIVERSITY COLL
ISTAb- A novel therapy to target staphylococcal toxins at the site of infections
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $600,000
Apr 1, 2019 – Mar 31, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Mining natively paired macque antibodies for Marburg virus protective antibodies
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $600,000
Apr 1, 2019 – Mar 31, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Development of a Universal Immunotherapeutic for Influenza Viruses
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $290,038
Mar 14, 2019 – Aug 31, 2020
Solicitation PA18-574 (2018) · Topic NIAID
Remodeled glycoprotein for broad protection against ebolaviruses
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $601,655
Jan 26, 2018 – Dec 31, 2020
Solicitation PA16-302 (2016) · Topic NIAID
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $1,861,259
Jul 1, 2017 – Jun 30, 2019
Solicitation PA16-303 (2016) · Topic NIAID · Research partner: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $594,931
Feb 15, 2017 – Jan 31, 2019
Solicitation PA15-270 (2015) · Topic r · Research partner: UNIV OF MARYLAND, COLLEGE PARK
Serotype independent therapeutic vaccine for Streptococcus pneumoniae
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $438,765
Feb 10, 2017 – Jul 31, 2019
Solicitation PA15-269 (2015) · Topic R
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $229,991
Jul 5, 2016 – Jun 30, 2017
Solicitation PA14-072 (2015) · Topic NIAID
Structure-guided redesign of monoclonal antibodies targeting conserved filovirus epitopes
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $284,365
Jul 1, 2016 – Jun 30, 2018
Solicitation PA15-269 (2015) · Topic R
Infection Site Targeted Antitoxin Antibody (ISTAb) against Clostridium difficile
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $230,063
Feb 1, 2015 – Jan 31, 2017
Solicitation PA14-071 (2015) · Topic NIAID
In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $599,996
Jun 15, 2014 – May 31, 2017
Solicitation PA10-123 (2015) · Topic NIAID
Immunotherapeutics to prevent HCV reinfection
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $600,000
Solicitation PA10-124 (2013) · Topic NIAID · Research partner: STANFORD UNIVERISTY
Development of Therapeutic Pan-Filovirus Macaque Monoclonal Antibodies
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $550,414
Solicitation PA10-123 (2012) · Topic NIAID · Research partner: Stub
A novel Structure Based Vaccine for staphylococcal alpha hemolysin
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $590,778
Solicitation PA10-123 (2012) · Topic NIAID · Research partner: Stub
Multi-specific Antibody Therapy by targeting S. aureus toxins and polysaccharides
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $593,316
Solicitation PA10-123 (2012) · Topic NIAID · Research partner: Stub
Development of a novel second-generation pan-filovirus subunit vaccine
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $600,000
Solicitation PA10-123 (2011) · Topic NIAID · Research partner: Stub
Development of a Panton Valentine Leukocidin bivalent vaccine
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $600,000
Solicitation PHS2010-2 (2010) · Topic NIAID
Therapeutic Human Hyperimmune Polyclonal Antibodies against Staphylococcal Enterotoxin B
SBIR Phase II · Department of Defense (Army) · 2008 · $1,159,390
Jan 15, 2009 – Nov 14, 2011
Solicitation 2007.2 (2007) · Topic A07-154
Therapeutic Human Hyperimmune Polyclonal Antibodies against Staphylococcal Enterotoxin B
SBIR Phase I · Department of Defense (Army) · 2007 · $109,774
Oct 19, 2007 – Apr 18, 2008
Solicitation 2007.2 (2007) · Topic A07-154
Anti-Id Vaccine for the Prevention of Endotoxemia
SBIR Phase I · Department of Health and Human Services · 1993 · $50,000
THE DEVELOPMENT OF MOLECULARLY PURE ANTIBODY REAGENTS TO VARIANT STRAINS OF MEASLES VIRUS
SBIR Phase I · Department of Health and Human Services · 1993 · $49,432
Showing the 25 most recent of 26 awards.
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Socio-economic status
Learn more about small business set-asidesProduct & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with INTEGRATED BIOTHERAPEUTICS, LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.